{"title":"白色念珠菌--为世界卫生组织真菌优先病原体清单提供信息的系统性回顾。","authors":"Sarika Parambath, Aiken Dao, Hannah Yejin Kim, Shukry Zawahir, Ana-Alastruey Izquierdo, Evelina Tacconelli, Nelesh Govender, Rita Oladele, Arnaldo Colombo, Tania Sorrell, Pilar Ramon-Pardo, Terence Fusire, Valeria Gigante, Hatim Sati, C Orla Morrissey, Jan-Willem Alffenaar, Justin Beardsley","doi":"10.1093/mmy/myae045","DOIUrl":null,"url":null,"abstract":"<p><p>Candida albicans is a common fungal pathogen and amongst the leading causes of invasive candidiasis globally. This systematic review examines the characteristics and global impact of invasive infections caused by C. albicans. We searched on PubMed and Web of Science for studies reporting on criteria such as mortality, morbidity, drug resistance, preventability, yearly incidence, and distribution/emergence during the period from 2016 to 2021. Our findings indicate that C. albicans is the most common Candida species causing invasive disease and that standard infection control measures are the primary means of prevention. However, we found high rates of mortality associated with infections caused by C. albicans. Furthermore, there is a lack of data on complications and sequelae. Resistance to commonly used antifungals remains rare. Although, whilst generally susceptible to azoles, we found some evidence of increasing resistance, particularly in middle-income settings-notably, data from low-income settings were limited. Candida albicans remains susceptible to echinocandins, amphotericin B, and flucytosine. We observed evidence of a decreasing proportion of infections caused by C. albicans relative to other Candida species, although detailed epidemiological studies are needed to confirm this trend. More robust data on attributable mortality, complications, and sequelae are needed to understand the full extent of the impact of invasive C. albicans infections.</p>","PeriodicalId":18586,"journal":{"name":"Medical mycology","volume":"62 6","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11210619/pdf/","citationCount":"0","resultStr":"{\"title\":\"Candida albicans-A systematic review to inform the World Health Organization Fungal Priority Pathogens List.\",\"authors\":\"Sarika Parambath, Aiken Dao, Hannah Yejin Kim, Shukry Zawahir, Ana-Alastruey Izquierdo, Evelina Tacconelli, Nelesh Govender, Rita Oladele, Arnaldo Colombo, Tania Sorrell, Pilar Ramon-Pardo, Terence Fusire, Valeria Gigante, Hatim Sati, C Orla Morrissey, Jan-Willem Alffenaar, Justin Beardsley\",\"doi\":\"10.1093/mmy/myae045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Candida albicans is a common fungal pathogen and amongst the leading causes of invasive candidiasis globally. This systematic review examines the characteristics and global impact of invasive infections caused by C. albicans. We searched on PubMed and Web of Science for studies reporting on criteria such as mortality, morbidity, drug resistance, preventability, yearly incidence, and distribution/emergence during the period from 2016 to 2021. Our findings indicate that C. albicans is the most common Candida species causing invasive disease and that standard infection control measures are the primary means of prevention. However, we found high rates of mortality associated with infections caused by C. albicans. Furthermore, there is a lack of data on complications and sequelae. Resistance to commonly used antifungals remains rare. Although, whilst generally susceptible to azoles, we found some evidence of increasing resistance, particularly in middle-income settings-notably, data from low-income settings were limited. Candida albicans remains susceptible to echinocandins, amphotericin B, and flucytosine. We observed evidence of a decreasing proportion of infections caused by C. albicans relative to other Candida species, although detailed epidemiological studies are needed to confirm this trend. More robust data on attributable mortality, complications, and sequelae are needed to understand the full extent of the impact of invasive C. albicans infections.</p>\",\"PeriodicalId\":18586,\"journal\":{\"name\":\"Medical mycology\",\"volume\":\"62 6\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11210619/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical mycology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/mmy/myae045\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mmy/myae045","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
白色念珠菌是一种常见的真菌病原体,也是全球侵袭性念珠菌病的主要病因之一。本系统性综述研究了由白念珠菌引起的侵袭性感染的特点和全球影响。我们在 PubMed 和 Web of Science 上搜索了 2016 年至 2021 年期间有关死亡率、发病率、耐药性、可预防性、年发病率和分布/出现等标准的研究报告。我们的研究结果表明,白念珠菌是导致侵袭性疾病的最常见念珠菌,标准的感染控制措施是主要的预防手段。然而,我们发现由白念珠菌引起的感染死亡率很高。此外,还缺乏有关并发症和后遗症的数据。对常用抗真菌药物产生抗药性的情况仍然很少见。虽然白念珠菌对唑类药物普遍易感,但我们发现一些证据表明耐药性在增加,尤其是在中等收入地区--值得注意的是,低收入地区的数据有限。白色念珠菌仍然对棘白菌素、两性霉素 B 和氟尿嘧啶敏感。我们观察到的证据表明,相对于其他念珠菌种类,由白念珠菌引起的感染比例正在下降,尽管还需要详细的流行病学研究来证实这一趋势。要全面了解侵袭性白念珠菌感染的影响,还需要更多关于可归因死亡率、并发症和后遗症的可靠数据。
Candida albicans-A systematic review to inform the World Health Organization Fungal Priority Pathogens List.
Candida albicans is a common fungal pathogen and amongst the leading causes of invasive candidiasis globally. This systematic review examines the characteristics and global impact of invasive infections caused by C. albicans. We searched on PubMed and Web of Science for studies reporting on criteria such as mortality, morbidity, drug resistance, preventability, yearly incidence, and distribution/emergence during the period from 2016 to 2021. Our findings indicate that C. albicans is the most common Candida species causing invasive disease and that standard infection control measures are the primary means of prevention. However, we found high rates of mortality associated with infections caused by C. albicans. Furthermore, there is a lack of data on complications and sequelae. Resistance to commonly used antifungals remains rare. Although, whilst generally susceptible to azoles, we found some evidence of increasing resistance, particularly in middle-income settings-notably, data from low-income settings were limited. Candida albicans remains susceptible to echinocandins, amphotericin B, and flucytosine. We observed evidence of a decreasing proportion of infections caused by C. albicans relative to other Candida species, although detailed epidemiological studies are needed to confirm this trend. More robust data on attributable mortality, complications, and sequelae are needed to understand the full extent of the impact of invasive C. albicans infections.
期刊介绍:
Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.